Medicare Enrolled

Dr. Rebecca Sharim, M.D.

Rheumatology · Allentown, PA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
3080 HAMILTON BLVD STE 300, Allentown, PA 18103
6107765038
In practice since 2009 (17 years)
NPI: 1669600292 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sharim from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sharim? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Sharim

Dr. Rebecca Sharim is a rheumatology specialist in Allentown, PA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Sharim performed 3,580 Medicare services across 402 unique beneficiaries.

Between the years covered by Open Payments, Dr. Sharim received a total of $12,919 from 28 pharmaceutical and/or device companies across 604 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Sharim is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 44% volume in PA $12,919 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,580
Medicare services
Top 44% in PA for rheumatology
402
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~211 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 3,000 $18 $47
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
220 $81 $211
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
112 $10 $65
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
81 $56 $149
Injection, methylprednisolone acetate, 40 mg 47 $6 $16
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
28 $57 $191
New patient office visit, complex (60-74 min) 27 $158 $394
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
23 $101 $265
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
23 $58 $170
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
19 $120 $283
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$12,919
Total received (2018-2024)
Avg $1,846/year across 7 years
Top 24% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
28
Companies
604
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,148 (94.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$720 (5.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$51 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,167
2023
$1,598
2022
$1,697
2021
$2,279
2020
$2,947
2019
$2,239
2018
$994

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$700
Amgen Inc.
$174
Aurinia Pharma U.S., Inc.
$125
UCB, Inc.
$125
Medtronic, Inc.
$43
Top 3 companies account for 85.6% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,952
UCB, Inc.
$1,422
AbbVie Inc.
$1,202
Horizon Therapeutics plc
$981
ABBVIE INC.
$936
Novartis Pharmaceuticals Corporation
$829
PFIZER INC.
$767
AbbVie, Inc.
$653
Janssen Biotech, Inc.
$521
Celgene Corporation
$362
AstraZeneca Pharmaceuticals LP
$356
Janssen Scientific Affairs, LLC
$224
Boehringer Ingelheim Pharmaceuticals, Inc.
$218
Lilly USA, LLC
$202
Sobi, Inc
$183
GlaxoSmithKline, LLC.
$178
Aurinia Pharma U.S., Inc.
$144
Collegium Pharmaceutical, Inc.
$144
SOBI, INC
$137
Alexion Pharmaceuticals, Inc.
$133
Genentech USA, Inc.
$103
Radius Health, Inc.
$77
Actelion Pharmaceuticals US, Inc.
$53
Flexion Therapeutics, Inc.
$44
Medtronic, Inc.
$43
Organon LLC
$28
Avion Pharmaceuticals
$13
Horizon Pharma plc
$12
Top 3 companies account for 43.2% of all-time payments
Associated products mentioned in payments ›
AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · DALIRESP · EVENITY · Enbrel · Gloperba · HUMIRA · Humira · ILARIS · INFLECTRA · JARDIANCE · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · OFEV · OLUMIANT · OPSUMIT · Otezla · PENNSAID · PREVNAR 20 · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIGNIA · SIMPONI · SIMPONI ARIA · SKYRIZI · SOLIRIS · STELARA · STIOLTO RESPIMAT · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TRADJENTA · TREMFYA · Tymlos · ULTOMIRIS · UPTRAVI · XELJANZ · XTAMPZA · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Allentown?
Compare rheumatologists in the Allentown area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
26
Per 100K population
6.9
County median income
$77,493
Nearest hospital
LEHIGH VALLEY HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Sharim is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 17 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Sharim experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Sharim performed 3,000 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sharim receive payments from pharmaceutical companies?
Yes. Dr. Sharim received a total of $12,919 from 28 companies across 604 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sharim's costs compare to other rheumatologists in Allentown?
Dr. Sharim's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sharim) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →